Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798463 | 0.87 | EPHX2 (0.42) | CPB2EPHX2EPHX1NPC1RAB9A | |
| SCHEMBL19808656 | 0.85 | KDM4E (0.33) | ADRB3EPHX2EPHX1NPC1RAB9A | |
| SCHEMBL19808698 | 0.85 | ALDH1A1 (0.44) | EPHX2KDM4EALDH1A1MAPK1 | |
| SCHEMBL20724755 | 0.70 | ALDH1A1 (0.44) | EPHX2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL19798465 | 0.70 | ALDH1A1 (0.55) | EPHX2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL19808217 | 0.69 | HSD11B1 (0.37) | — | |
| SCHEMBL7101866 | 0.69 | KEAP1 (0.42) | ADRB3KDM4EALDH1A1 | |
| SCHEMBL19798448 | 0.69 | ALDH1A1 (0.43) | EPHX2KDM4EALDH1A1MAPK1 | |
| SCHEMBL19808685 | 0.69 | EPHX2 (0.71) | EPHX2 | |
| SCHEMBL19808451 | 0.68 | ALDH1A1 (0.37) | EPHX2KDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | CPB2 2109/4885ADRB3 1557/4885EPHX2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.